Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells

Cell Death and Disease

Volumn 5, Issue 9, 2014, Pages

  Hou, J K ^a   Huang, Y ^b   He, W ^b   Yan, Z W ^b   Fan, L ^b   Liu, M H ^b   Xiao, W L ^c   Sun, H D ^c   Chen, G Q ^a,b,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c KUNMING INSTITUTE OF BOTANY   (China)

^d SHANGHAI CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENANTHIN; CYSTEINE; CYTOTOXIC AGENT; DITERPENOID; PEROXIREDOXIN 1; PEROXIREDOXIN 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KAURANE DERIVATIVE; PEROXIREDOXIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; ISODON; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; OXIDATIVE STRESS; PATHOLOGY; PLANT LEAF; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ISODON ADENANTHUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DITERPENES, KAURANE; HEP G2 CELLS; HUMANS; ISODON; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OXIDATIVE STRESS; PEROXIREDOXINS; PLANT LEAVES; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84909646248     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.345     Document Type: Article

References (45)

1. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 2003; 300: 650-653.
2. Rhee SG, Woo HA. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H2O2, and protein chaperones. Antioxid Redox Signal 2011; 15: 781-794.
3. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006; 312: 1882-1883.
4. Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol 2011; 7: 504-511.
5. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 2005; 38: 1543-1552.
6. Hall A, Karplus PA, Poole LB. Typical 2-Cys peroxiredoxins-structures, mechanisms and functions. FEBS J 2009; 276: 2469-2477.
7. Nystrom T, Yang J, Molin M. Peroxiredoxins, gerontogenes linking aging to genome instability and cancer. Genes Dev 2012; 26: 2001-2008.
8. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 2009; 28: 1505-1517.
9. Egler RA, Fernandes E, Rothermund K, Sereika S, de Souza-Pinto N, Jaruga P et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 2005; 24: 8038-8050.
10. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003; 424: 561-565.
11. Zhang B, Wang Y, Su Y. Peroxiredoxins a novel target in cancer radiotherapy. Cancer Lett 2009; 286: 154-160.
12. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 2005; 11: 571-578.
13. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
14. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
15. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012; 56(Suppl 1): S75-S87.
16. Li J, Xu Y, Long XD, Wang W, Jiao HK, Mei Z et al. Cbx4 governs HIF-1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer Cell 2014; 25: 118-131.
17. Feng GS. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 2012; 21: 150-154.
18. Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis 2014; 5: e996.
19. Mei Z, Jiao H, Wang W, Li J, Chen G, Xu Y. Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L. Sci China Life Sci 2014; 57: 610-617.
20. Lee JM, Han KH. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach-Asian perspective. Oncology 2010; 78(Suppl 1): 167-171.
21. Liu CX, Yin QQ, Zhou HC, Wu YL, Pu JX, Xia L et al. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol 2012; 8: 486-493.
22. Liu CX, Zhou HC, Yin QQ, Wu YL, Chen GQ. Targeting peroxiredoxins against leukemia. Exp Cell Res 2013; 319: 170-176.
23. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011; 61: 31-49.
24. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-837.
25. Wang J, Lin D, Peng H, Huang Y, Huang J, Gu J. Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species. Cell Death Dis 2013; 4: e945.
26. Wani R, Qian J, Yin L, Bechtold E, King SB, Poole LB et al. Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species. Proc Natl Acad Sci USA 2011; 108: 10550-10555.
27. Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J et al. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 2014; 21: 612-623.
28. Yang J, Su Y, Richmond A. Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Free Radic Biol Med 2007; 42: 1369-1380.
29. Francischetti IM, Gordon E, Bizzarro B, Gera N, Andrade BB, Oliveira F et al. Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malaria. PLoS One 2014; 9: e87140.
30. Muchowicz A, Firczuk M, Chlebowska J, Nowis D, Stachura J, Barankiewicz J et al. Adenanthin targets proteins involved in the regulation of disulphide bonds. Biochem Pharmacol 2014; 89: 210-216.
31. Jiang B, Yang H, Li ML, Hou AJ, Han QB, Wang SJ et al. Diterpenoids from Isodon adenantha. J Nat Prod 2002; 65: 1111-1116.
32. Kumsta C, Jakob U. Redox-regulated chaperones. Biochemistry 2009; 48: 4666-4676.
33. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006; 10: 175-176.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
35. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475: 231-234.
36. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241-252.
37. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
38. Shen HM, Liu ZG. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006; 40: 928-939.
39. Ishii T, Warabi E, Yanagawa T. Novel roles of peroxiredoxins in inflammation, cancer and innate immunity. J Clin Biochem Nutr 2012; 50: 91-105.
40. Le Bras M, Clement MV, Pervaiz S, Brenner C. Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histol Histopathol 2005; 20: 205-219.
41. Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu JH et al. Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol 2014; 31: 786.
42. Yue HY, Cao J, Cui JF, Dai Z, Su JJ, Duan XX et al. [The expression of peroxiredoxin II in hepatocellular carcinoma and its significance]. Zhonghua Gan Zang Bing Za Zhi 2007; 15: 366-369.
43. Aguilar-Melero P, Prieto-Alamo MJ, Jurado J, Holmgren A, Pueyo C. Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1. J Proteomics 2007; 79: 161-171.
44. Yin QQ, Liu CX, Wu YL, Wu SF, Wang Y, Zhang X et al. Preventive and therapeutic effects of adenanthin on experimental autoimmune encephalomyelitis by inhibiting NF-kappaB signaling. J Immunol 2013; 191: 2115-2125.
45. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008; 8: 16.